DANIEL LAMARRE, Ph.D.
- Principal Investigator, Molecular Immunovirology Laboratory, Institute for Research in Immunology and Cancer
- Full Professor, Department of Medicine, Faculty of Medicine, Université de Montréal
- Director, Hepatology/Gastro-enterology Research Axis, Centre de recherche du Centre hospitalier de l’Université de Montréal (CHUM)
AWARDS & HONOURS
- 2009 GENESIS Award - Biotechnology Award of Tomorrow
- Université de Montréal Novartis /Canadian Liver Foundation Hepatology Research Chair, 2003–
- R&D Award, Boehringer Ingelheim, 2000
- Postdoctoral Fellow, The Cancer Research Society, 1988-1990
- Postdoctoral Fellow, Fonds de la recherche en santé du Québec (FRSQ), 1987-1988
- Doctoral Fellowship, Fonds pour la formation des chercheurs et l’aide à la recherche (FCAR), 1984-1987
TRAINING
- Postdoctoral training with Rafick-Pierre Sékaly, Clinical Research Institute of Montreal, 1987-1990
- Ph.D. in biochemistry with Guy Gustave Poirier, Université de Sherbrooke,
1984-1987
- M.Sc. in clinical sciences with Alcide Chapdelaine, Université de Montréal, 1978-1981
RESEARCH SUPPORT
- Canadian Foundation for Innovation
- Canadian Institutes of Health Research
- Génome Québec
- Research Centre of the University of Montreal Hospital Centre
- Institut national de la santé et de la recherche médicale (INSERM)
- Ministère du développement économique, de l'innovation et de l'exportation
- Université de Montréal
Daniel Lamarre began his academic career in 2003, after having spent some thirteen years as a research scientist in the pharmaceutical industry. Working at the Université de Montréal today, he leads the Molecular Immunovirology Laboratory at the Institute for Research in Immunology and Cancer (IRIC) and is full professor at the Department of Medicine and holds the Université de Montréal Novartis/Canadian Liver Foundation Hepatology Research Chair.
After his doctoral studies in biochemistry at the Université de Sherbrooke and postdoctoral training in immunology at the Clinical Research Institute of Montreal, Daniel Lamarre joined Boehringer Ingelheim, formerly Bio-Méga, where he did research on therapeutic agents for viral infections. He played a key role in the discovery of the HIV inhibitor "palinavir". In 1995, he was appointed HCV Research Coordinator at Boehringer Ingelheim. Dr. Lamarre and his team developed the experimental drug BILN 2061, the first compound in its class to be evaluated in subjects infected with HCV. In the clinical research phase, BILN 2061 has shown its ability to reduce the viral load by a factor up to 10,000 in the first 24 hours of treatment, demonstrating for the first time that this class of antiviral represents a very promising therapeutic approach.
Currently at IRIC, Daniel Lamarre devoted his efforts to studying the ability of HCV to interfere with immune mechanisms and lead to the development of serious liver diseases such as cirrhosis and hepatocellular carcinoma in affected persons.
Daniel Lamarre is also responsible for IRIC’s High Throughput Screening Facility, and with it team provides expertise in new molecular target identification as well as finding target-specific molecules in support of both fundamental and clinical research projects via the automated screening of chemical and RNAi libraries.
Daniel Lamarre is CEO and general manager of IRICoR, a new Canadian Centre of Excellence in Commercialization of Research (CECR) in Therapeutics Discovery, which has for mission to move basic discoveries further along the development chain and set up broader partnerships between academia and the biopharmaceutical sector.
SELECTED PUBLICATIONS
Baril M, Racine ME, Penin F, Lamarre D. (2009) MAVS dimer is a crucial signaling component of innate immunity and the target of HCV NS3/4A protease. J Virol. 83(3):1299-311.
Raymond VA, Selliah S, Éthier C, Houle R, Jouan L, Maniere T, Lamarre D, Willems B, Bilodeau M. (2009) Primary cultures of human hepatocytes isolated from hepatitis C virus infected cirrhotic livers as a model to study hepatitis C infection. Liver Int. 29(6):942-9.
Voisin, L., Julien, C., Duhamel, S., Gopalbhai, K., Claveau, I., Saba-El-Leil, M.K., Rodrigue-Gervais, I.G., Gaboury, L., Lamarre, D., Basik, M., Meloche, S. (2008) Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induces the formation of metastatic tumors. BMC Cancer 8:337.
Rodrigue-Gervais IG, Jouan L, Beaulé G, Sauvé D, Bruneau J, Willems B, Sékaly RP, Lamarre D. (2007) Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients. J Virol. 81(11):5537-46.
Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maitre C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, Tsantrizos YS, Lamarre D (2004) Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061. J Med Chem 47:1605-1608.
Lamarre D, Anderson PC, Bailey M, Beaulieu P, et al. (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
Lamarre D, Croteau G, Wardrop E, Bourgon L, Thibeault D, Clouette C, Vaillancourt M, Cohen E, Pargellis C, Yoakim C, Anderson PC (1997) Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 41:965-971.
Lamarre D, Ashkenazi A, Fleury S, Smith DH, Sékaly RP, Capon DJ (1989) The MHC-binding and gp120-binding functions of CD4 are separable. Science 245:743-746.
Lamarre D, Ashkenazi A, Fleury S, Smith DH, Sékaly RP, Capon DJ (1989) The MHC-binding and gp120-binding functions of CD4 are separable. Science 245:743-746
Top
<< Back to Investigator List
